Corpus overview


Overview

MeSH Disease

Human Phenotype

Shock (7)

Hypertension (3)

Fever (2)

Cough (2)

Dyspnea (2)


Transmission

Seroprevalence
    displaying 1 - 7 records in total 7
    records per page




    Red blood SERO cell distribution width (RDW) in Hospitalized COVID-19 Patients

    Authors: Preethi Ramachandran; Mahesh Gajendran; Abhilash Perisetti; Karim Osama Elkholy; Abhishek Chakraborti; Giuseppe Lippi; Hemant Goyal

    doi:10.1101/2020.06.29.20143081 Date: 2020-07-03 Source: medRxiv

    Introduction: Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 MESHD (SARS-CoV-2), is causing dramatic morbidity and mortality worldwide. The Red Blood SERO Cell Distribution Width (RDW) has been strongly associated with increased morbidity and mortality in multiple diseases. Objective: To assess if elevated RDW is associated with unfavorable outcomes in hospitalized COVID-19. Methods: We retrospectively studied clinical outcomes of hospitalized COVID-19 patients for their RDW values. In-hospital mortality was defined as primary outcome, while septic shock MESHD shock HP, need for mechanical ventilation, and length of stay (LOS) were secondary outcomes. Results- A total of 294 COVID-19 patients were finally studied. Overall prevalence SERO of increased RDW was 49.7% (146/294). RDW was associated with increased risk of in-hospital mortality (aOR, 4.5; 95%CI, 1.4-14.3) and septic shock MESHD shock HP (aOR, 4.6; 95%CI, 1.4-15.1) after adjusting for anemia HP anemia MESHD, ferritin, and lactate. The association remained unchanged even after adjusting for other clinical confounders such as age TRANS, sex, body mass index, coronary artery disease MESHD, hypertension HP hypertension MESHD, diabetes mellitus HP diabetes mellitus MESHD, and chronic obstructive pulmonary disease HP chronic obstructive pulmonary disease MESHD. No association was found instead with mechanical ventilation and median LOS. Conclusion: Elevated RDW in hospitalized COVID-19 patients is associated with a significantly increased risk of mortality and septic shock MESHD shock HP.

    National Smoking Rates Correlate Inversely with COVID-19 Mortality

    Authors: Michael J Norden; David H. Avery; Justin G Norden; David R Haynor

    doi:10.1101/2020.06.12.20129825 Date: 2020-06-14 Source: medRxiv

    ABSTRACT Introduction: Recent studies show cigarette smokers are markedly under-represented among patients hospitalized for COVID-19 in over a dozen countries. It is unclear if this may be related to confounding factors such as age TRANS distribution, access to care, and inaccurate records. We hypothesized that these concerns could be avoided by studying smoking prevalence SERO in relation to COVID-19 mortality. Since climate has been identified as a factor in COVID-19, we studied groups of countries with relatively comparable temperatures. Methods: The 20 hottest and 20 coldest countries in the Johns Hopkins Mortality Analysis database with a minimum mortality rate of .3 deaths/100,000 were selected on the basis of the average temperatures of their largest city. Mortality rates were determined as of May 1, 2020 and correlated with national smoking rate adjusting for sex ratio, obesity HP obesity MESHD, temperature, and elderly TRANS population. Results: A highly significant inverse correlation between current daily smoking prevalence SERO and COVID-19 mortality rate was noted for the group of hot countries (R=-.718, p = .0002), cold countries (R=-.567, p=.0046), and the combined group (R=-.324, p=.0207). However, after adjustments only the regression for hot countries and the combined group remained significant. In hot countries, for each percentage point increase in smoking rate mortality decreased by .147 per 100,000 population (95% CI .102- 192, p=.0066). This resulted in mortality rates several-fold elevated in the countries with the lowest smoking rates relative to the highest smoking rates. In the combined group, mortality decreased by .257 per 100,000 population (95% CI .175-.339, p=.0034). Discussion: These findings add support to the finding of an inverse relationship between current smoking and seriously symptomatic COVID-19. However, we conclude that the difference in mortality between the highest and lowest smoking countries appears too large to be due primarily to the effects of smoking per se. A potentially beneficial effect of smoking is surprising, but compatible with a number of hypothetical mechanisms which deserve exploration: 1) Studies show smoking alters ACE2 expression which may affect COVID-19 infection MESHD or its progression to serious lung pathology. 2) Nicotine has anti-inflammatory activity and also appears to alter ACE2 expression. 3) Nitric oxide in cigarette smoke is known to be effective in treating pulmonary hypertension MESHD hypertension HP and has shown in vitro antiviral effects including against SARS-CoV-2. 4) Smoking has complicated effects on the immune system involving both up and down regulation, any of which might alone or in concert antagonize progression of COVID-19. 5) Smokers are exposed to hot vapors which may stimulate immunity in the respiratory tract by various heat-related mechanisms (e.g. heat shock HP proteins). Studies of steam and sauna treatments have shown efficacy in other viral respiratory conditions. At this time there is no clear evidence that smoking is protective against COVID-19, so the established recommendations to avoid smoking should be emphasized. The interaction of smoking and COVID-19 will only be reliably determined by carefully designed prospective study, and there is reason to believe that there are unknown confounds that may be spuriously suggesting a protective effect of smoking. However, the magnitude of the apparent inverse association of COVID-19 and smoking and its myriad clinical implications suggest the importance of further investigation.

    Clinical symptoms, comorbidities and complications features in severe and non-severe patients with COVID-19: a systematic review and meta-analysis without cases duplication

    Authors: Zhufeng Wang; Hongsheng Deng; Changxing Ou; Jingyi Liang; Yingzhi Wang; Mei Jiang; Shiyue Li

    doi:10.21203/rs.3.rs-30787/v1 Date: 2020-05-21 Source: ResearchSquare

    Background: The pandemic of COVID-19 posed a challenge to global healthcare. The mortality rates of severe cases range from 8.1% to 31.8%, and it is particularly important to identify risk factors that aggravate the disease.Methods: We performed a systematic review of the literature with meta-analysis, using 7 databases to assess clinical characteristics, comorbidities and complications in severe and non-severe patients with COVID-19. All the observational studies were included. We performed a random or fixed effects model meta-analysis to calculate the pooled proportion and 95% CI. Measure of heterogeneity was estimated by Cochran’s Q statistic, I2 index and P value.Results: 4881 cases from 25 studies related to COVID-19 were included. The most prevalent comorbidity was hypertension HP hypertension MESHD (severe: 33.4%, 95% CI: 25.4% - 41.4%; non-severe 21.6%, 95% CI: 9.9% - 33.3%), followed by diabetes MESHD (severe: 14.4%, 95% CI: 11.5% - 17.3%; non-severe: 8.5%, 95% CI: 6.1% - 11.0%). The prevalence SERO of ARDS, AKI and shock HP were all higher in severe cases, with 41.1% (95% CI: 14.1% - 68.2%), 16.4% (95% CI: 3.4% - 29.5%) and 19.9% (95% CI: 5.5% - 34.4%), rather than 3.0% (95% CI: 0.6% - 5.5%), 2.2% (95% CI: 0.1% - 4.2%) and 4.1% (95% CI -4.8% - 13.1%) in non-severe patients, respectively. The death rate was higher in severe cases (30.3%, 95% CI: 13.8% - 46.8%) than non-severe cases (1.5%, 95% CI: 0.1% - 2.8%).Conclusions: Hypertension HP Hypertension MESHD, diabetes MESHD and cardiovascular diseases MESHD may be risk factors for COVID-19 patients to develop into severe cases.

    Sepsis HP Sepsis MESHD and septic shock MESHD shock HP in COVID-19: a scoping review of the research data

    Authors: Sulaiman Lakoh; Darlinda F. JIBA; Mamadu BALDEH; Alren O. VANDY; Hassan BENYA; Marta LADO; Stephen SEVALIE; George A. YENDEWA; Foday SAHR

    doi:10.21203/rs.3.rs-30474/v1 Date: 2020-05-20 Source: ResearchSquare

    Background Sepsis HP Sepsis MESHD is a major contributor to global mortality with an estimated 700, 000 sepsis HP sepsis MESHD-related deaths annually. As sepsis HP sepsis MESHD is an acute complication of COVID-19, the ongoing pandemic can increase its global burden. Despite this, there is still limited research evidence on COVID-19 and sepsis HP sepsis MESHD. In this scoping review, we described the research data on sepsis HP sepsis MESHD and septic shock MESHD shock HP among patients with COVID-19.Methods We adapted Arksey and O’Malley framework by reviewing relevant studies published on medRxiv, PubMed, and Google Scholar between January 01, 2020, and April 16, 2020, on sepsis HP sepsis MESHD and septic shock MESHD shock HP with the publication language restriction to English. The findings included the prevalence SERO and outcome of COVID-19 patients with sepsis HP sepsis MESHD or septic shock MESHD shock HP, sepsis HP sepsis MESHD criteria, laboratory data, and the treatment given to COVID patients.Results Of the 16 eligible articles included in this review, 13 (81.2%) were conducted in China. With the exception of one article, the research work for all the articles was conducted in adult TRANS patients. The articles were retrospective studies (12, 75%), case reports (3, 18.8%) and prospective observational studies (1,6.2%). The estimated prevalence SERO of sepsis HP sepsis MESHD and septic shock MESHD shock HP range from 6.8–100% and 4–28.9%, respectively. Serum SERO lactate, platelets, C-reactive protein, white cell counts, and procalcitonin were elevated in 24.5%, 6.2%, 31.2%, 62.5%, 43.8% and 37.5% of the articles, respectively. Bacterial cultures were documented in 4(25%) of the eligible articles. 12 (75%) and 11 (68.8%) articles documented the use of antivirals and antibiotics, respectively. Other antimicrobials used among COVID-19 patients were hydroxychloroquine (1,6.3%), chloroquine (1, 6.3%), and unspecified antifungal drugs (2, 12.5%). Supportive therapies like oxygen therapy, mechanical ventilation, and fluid therapy were documented in 12(75%), 13 (81.3%), and 2 (12.5%) articles, respectively. The highest and lowest mortality among the study participants is 29.8% (134) and 5.4% (12), respectively.Conclusion There is a paucity of data in the literature on sepsis HP sepsis MESHD in COVID-19 despite its high burden among the COVID-19 patient population resulting in a high rate of antimicrobial use that is not backed by clearly documented microbiology laboratory support. Research is needed to understand the burden of sepsis HP sepsis MESHD in COVID-19.

    Acute gastrointestinal injury MESHD in critically ill MESHD patients with coronavirus disease MESHD 2019 in Wuhan, China

    Authors: Jia-Kui Sun

    doi:10.1101/2020.03.25.20043570 Date: 2020-03-27 Source: medRxiv

    Background: To investigate the prevalence SERO and outcomes of acute gastrointestinal injury MESHD ( AGI MESHD) in critically ill MESHD patients with coronavirus disease MESHD 2019 (COVID-19). Methods: In this clinical retrospective study, demographic data, laboratory parameters, AGI MESHD grades, clinical severity and outcomes were collected. The primary endpoints were AGI MESHD incidence and 28-day mortality, the secondary endpoints were organ dysfunction MESHD and septic shock MESHD shock HP incidence. Results: From February 10 to March 10 2020, 83 critically ill patients of 1314 patients with COVID-19 were enrolled. Seventy-two (86.7%) patients had AGI MESHD during hospital stay, of them, 30 had AGI MESHD grade I, 35 had AGI MESHD grade II, 5 had AGI MESHD grade III, and 2 had AGI MESHD grade IV. The incidence of AGI MESHD grade II and above was 50.6%. As of March 16, 40 (48.2%) patients died within 28 days of admission, the median hospital stay was 12.0 days, ranging from 3 days to 27 days. Multiple organ dysfunction syndrome MESHD developed in 58 (69.9%) patients, septic shock MESHD shock HP in 16 (19.3%) patients. Patients with worse AGI MESHD grades had worse clinical variables, higher septic shock MESHD shock HP incidence and 28-day mortality. Sequential organ failure assessment scores (SOFA) (95% CI, 1.374-2.860; P <0.001), white blood SERO cell (WBC) counts (95% CI, 1.037-1.379; P =0.014), duration of mechanical ventilation (MV) (95% CI, 1.020-1.340; P =0.025) were risk factors for the development of AGI MESHD grade II and above. Non-survivors were accompanied by higher incidence of AGI MESHD grade III to IV than survivors (17.5% vs. 0.0%, P =0.004). Conclusions: The AGI MESHD incidence was 86.7%, and hospital mortality was 48.2% in critically ill patients with COVID-19. SOFA scores, WBC counts, and duration of MV were risk factors for the development of AGI MESHD grade II and above. Patients with worse AGI MESHD grades had worse clinical severity variables, higher septic shock MESHD shock HP incidence and 28-day mortality.

    Clinical features, treatments and outcomes of severe and critical severe patients infected with COVID-19: A system review and meta-analysis

    Authors: Hai-yue Zhang; Fang-zhou Jiao; Xiao-jun Wu; Min Shang; Yu-chuan Luo; Zuo-jiong Gong

    doi:10.21203/rs.3.rs-17307/v1 Date: 2020-03-11 Source: ResearchSquare

    Backgrounds: The outbreak of COVID-19 caused by a novel coronavirus, SARS-CoV-2, has been listed as a public health emergency of international concern by WHO. Most COVID-19 patients presented with a mild infection MESHD, but many challenges exist in therapy of severe and critical severe patients. This paper systematically reviewed clinical features, treatments and outcomes of severe and critical severe patients infected COVID-19. Methods: The clinical, laboratory, imaging features, treatment and outcomes of COVID-19 were collected. The data were analyzed by using STATA 15 statistical software to estimate the prevalence SERO and 95% CI in severe and critical severe patients with COVID-19. A random or fixed effect model was used to estimate the prevalence SERO and 95% CI. Results: After screening, 8 studies including a total of 275 patients were included in this meta-analysis. The percentage of severe and critical severe patients in confirmed COVID-19 cases was 25% (95% CI 16-36%). Fever HP Fever MESHD, cough HP cough MESHD, dyspnea HP dyspnea MESHD, lymphopenia HP lymphopenia MESHD and bilateral distribution of patchy shadows were the most prevalent findings in these patients. Utilization rate of antiviral drugs, corticosteroid, non-invasive ventilation, invasive mechanical ventilation was high in therapy strategies. The most prevalent complications were ARDS, shock HP, and acute cardiac injury MESHD. Discussion: Severe and critical severe COVID-19 patients usually had complications even a fatal outcome. As vaccines and anti-coronaviral drugs are under development, the principles of treatment for these patients should be focused on improving oxygenation, lung protective and function support of multiple organs.

    Clinical, Laboratory and Imaging Features of COVID-19: A Systematic Review and Meta-analysis

    Authors: Alfonso J. Rodriguez-Morales; Jaime A. Cardona-Ospina; Estefanía Gutiérrez-Ocampo; Rhuvi Villamizar-Peña; Yeimer Holguin-Rivera; Juan Pablo Escalera-Antezana; Lucia Elena Alvarado-Arnez; D. Katterine Bonilla-Aldana; Carlos Franco-Paredes; Andrés F. Henao-Martinez; Alberto Paniz-Mondolfi; Guillermo J. Lagos-Grisales; Eduardo Ramírez-Vallejo; Jose A. Suárez; Lysien I. Zambrano; Wilmer E. Villamil-Gómez; Graciela J. Balbin-Ramon; Ali A. Rabaan; Harapan Harapan; Kuldeep Dhama; Hiroshi Nishiura; Hiromitsu Kataoka; Tauseef Ahmad; Ranjit Sah

    id:10.20944/preprints202002.0378.v3 Date: 2020-03-11 Source: Preprints.org

    Introduction: An epidemic of Coronavirus Disease MESHD 2019 (COVID-19) begun in December 2019 in China, causing a Public Health Emergency of International Concern. Among raised questions, clinical, laboratory, and imaging features have been partially characterized in some observational studies. No systematic reviews have been published on this matter. Methods: We performed a systematic literature review with meta-analysis, using three databases to assess clinical, laboratory, imaging features, and outcomes of COVID-19 confirmed cases TRANS. Observational studies, and also case reports, were included and analyzed separately. We performed a random-effects model meta-analysis to calculate the pooled prevalence SERO and 95% confidence interval (95%CI). Results: 660 articles were retrieved (1/1/2020-2/23/2020). After screening by abstract/title, 27 articles were selected for full-text assessment. Of them, 19 were finally included for qualitative and quantitative analyses. Additionally, 39 case report articles were included and analyzed separately. For 656 patients, fever HP fever MESHD (88.7%, 95%CI 84.5-92.9%), cough HP (57.6%, 40.8-74.4%) and dyspnea HP dyspnea MESHD (45.6%, 10.9-80.4%) were the most prevalent manifestations. Among the patients, 20.3% (95%CI 10.0-30.6%) required intensive care unit (ICU), with 32.8% presenting acute respiratory distress HP respiratory distress MESHD syndrome ( ARDS MESHD) (95%CI 13.7-51.8), 6.2% (95%CI 3.1-9.3) with shock HP shock MESHD and 13.9% (95%CI 6.2-21.5%) of hospitalized patients with fatal outcomes (case fatality rate, CFR).Conclusion: COVID-19 brings a huge burden to healthcare facilities, especially in patients with comorbidities. ICU was required for approximately 20% of polymorbid, COVID-19 infected MESHD patients and this group was associated with a CFR of over 13%. As this virus spreads globally, countries need to urgently prepare human resources, infrastructure, and facilities to treat severe COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.